1600-1830

Scientific Advisory Meeting for invited experts to prioritise the key science research areas moving forward

1830

Speakers' Reception for invited guests

0830-0900

Registration & Coffee

0900

Welcome & Introduction

Tony Greco, Conference Chairman

Sir Mike Richards, National Cancer Director

 AM

MANAGING THE PATIENT PATHWAY

Key recommendations of the NICE Guideline and update on NCAT Peer Review Measures. Richard Osborne, Consultant in Medical Oncology, Dorset Cancer Centre. Lead Clinician, CUP Guideline Development Group

Developing a new pathway for CUP patients at Chesterfield Royal Hospital – David Brooks, Macmillan Consultant in Palliative Medicine & Member of the NICE Guideline Development Group

CUP epidemiology & health service utilisation in Australia - Claire Vajdic, Team Leader, Cancer Aetiology and Prevention Group, Prince of Wales Clinical School, University of New South Wales

Coffee

Expert panel and audience discussion. Implementing the Guideline/ Measures and improving the patient pathway.

PATIENT EXPERIENCE

Recent research findings:

UK – Julia Addington Hall, Professor of End of Life Care, University of Southampton

Australia - Penelope Schofield, Research Director, Department of Nursing and Supportive Care Research, Peter MacCallum Cancer Centre, Australia

Expert panel and audience discussion. Understanding the patient and carer needs. How can the experience be improved?

1300-1400

Lunch

 PM

SCIENTIFIC RESEARCH

UK - Preliminary findings from the CUP One Trial and putative CUP research projects. Harpreet Wasan, Principal Investigator, CUP-One Trial

Australia – Update on Peter MacCallum Cancer Centre studies on CUP and putative projects. Penelope Schofield, Peter MacCallum Cancer Centre

USA - Update of the Sarah Cannon Research Institute Studies and the Expanding Role of Molecular Profile Diagnoses. Tony Greco, Director, The Sarah Cannon Cancer Center

Tea

Keynote - The biology of CUP: have we made any progress towards understanding the disease and in targeting strategic molecular pathways? Nicholas Pavlidis, Director of the Medical Oncology Department, University of Ioannina, Greece

Expert panel & audience discussion. Does CUP have a specific genetic signature? Are specific CUP genetic signatures other than local tumour growth and metastasis control pathways expected? Do CUP patients with specific molecular profile tissue of origin diagnoses treated with site specific treatments have similar outcomes to patients with known metastatic carcinomas? Will therapeutic targeting of specific pathways in CUP be any different compared to other known advanced cancers? What are the research priorities moving forward?

1715-1730

Close – Tony Greco